Tu canal independiente de oncología en español
Regístrate aquí para recibir más contenidos
Registrarse
OncoBites te trae los resúmenes y
presentaciones más relevantes del congreso
ASCOGI 2026
Top resúmenes y presentaciones
Tislelizumab plus chemoradiotherapy (CRT) versus CRT or
chemotherapy (CT) as the neoadjuvant treatment for
patients (pts) with locally advanced
gastric/gastroesophageal junction adenocarcinoma
(GC/GEJC): A multicenter, randomized controlled,
open-label, phase IIb study (TERRIFIC).
286
Liposomal irinotecan, carboplatin or oxaliplatin (LyRICX)
with or without nivolumab in the first-line treatment of
metastatic or irresectable esophagogastric
adenocarcinoma: A randomized phase 2 study.
LBA287
Phase 2 ILUSTRO trial of 1L zolbetuximab plus mFOLFOX6 and
nivolumab in patients with CLDN18.2+ locally advanced (LA)
unresectable or metastatic gastric or gastroesophageal
junction (mG/GEJ) adenocarcinoma.
LBA284
CRITICS-II: A multicenter randomized phase II trial of
neo-adjuvant chemotherapy followed by surgery versus
neo-adjuvant chemotherapy and subsequent
chemoradiotherapy followed by surgery versus
neo-adjuvant chemoradiotherapy followed by surgery in
resectable gastric cancer.
283
Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line
(1L) HER2-positive (HER2+) locally advanced, unresectable, or
metastatic gastroesophageal adenocarcinoma (mGEA):
Primary analysis from HERIZON-GEA-01.
LBA285
ASCOGI 2026
ESOFAGOGÁSTRICO
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Phase II study of durvalumab plus olaparib in patients
with metastatic pancreatic cancer and DNA damage
repair gene alterations.
724
Adjuvant pembrolizumab for participants with
hepatocellular carcinoma and complete radiologic
response after surgical resection or local ablation: The
phase 3 keynote-937 study.
477
Efficacy and safety of lirafugratinib in FGFRi-naïve
cholangiocarcinoma (CCA) patients harboring FGFR2
fusions/rearrangements (FGFR2 f/r).
476
ALTOPANC: Local ablative therapies in oligometastatic
pancreatic adenocarcinoma—A bi-national
French-Belgian retrospective study.
728
Preliminary phase 1 results of INCB161734, a novel oral
Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy
or in combination with chemotherapy for
advanced/metastatic pancreatic duct adenocarcinoma
(PDAC).
654
ASCOGI 2026
HEPATOBILIOPANCREÁTICOS
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Longitudinal study on the influence of physical activity in
managing cancer-related fatigue in patients with
colorectal cancer
16
Colorectal Cancer Metastatic dMMR Immunotherapy
(COMMIT) study: A randomized phase III study of
atezolizumab (atezo) monotherapy versus
mFOLFOX6/bevacizumab/atezo (FFX/bev) in the first-line
treatment of patients (pts) with deficient DNA mismatch
repair (dMMR) or microsatellite instability-high (MSI-H)
metastatic colorectal cancer (mCRC)—
NRG-GI004/SWOG-S1610.
14
GLP-1 receptor agonist vs aspirin for primary prevention of
colorectal cancer: Evidence from a real-world head-to-head
comparison
18
Diffusion-weighted magnetic resonance imaging versus
surgical staging in patients with colorectal peritoneal
metastases: The multicenter, international, randomized
controlled DISCO trial
15
BREAKWATER: Primary analysis of first-line (1L) encorafenib
+ cetuximab (EC) + FOLFIRI in BRAF V600E-mutant
metastatic colorectal cancer (mCRC)
13
ASCOGI 2026
COLORRECTAL
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse